Question 1: As the study is jointly funded, what impact does this have on the current cash runway to end FY24?
Question 2: Even with no impact (assuming fully funded or considered), there appears to be sufficient cash for 12 months, which really means there needs to be a a funding update either this or next quarter. Will it be CR or partnership. My bet would be partnership of sorts, fingers crossed it's not from a position of weakness.
Ann: Approval to start Efti & Bavencio trial in urothelial cancer, page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 28.5¢ | $751.3K | 2.589M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 307462 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 118494 | 4 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |